Marck Biosciences Ltd on Wednesday said it has sold a minority stake to Tata Capital Healthcare Fund for Rs 45 crore to part-fund its new expansion project worth about Rs 80 crore.
Marck Bio said Tata Capital will invest Rs 45 crore in March Biosciences for 13 to 15% stake, depending on future converts.
Besides, Tata Capital will also pick up 6% stake of IFCI Venture for Rs 15 crore at a valuation of Rs 225 crore. Thus, Tata Capital will hold around 19-22% combined stake in Marck, said Bhavesh Patel, Managing Director.
The Ahmedabad-based Marck Biosciences, manufacturer and marketer of sterile liquids pharmaceutical dosages using the Blow-Fill-Seal (BFS) technology, is targeting a top line growth of 62% while the PBDIT is aimed at 37% and net profit to reach at 17-18%.
He said the fund infusion from Tata Capital will be invested for further expansion of capacities of the new project. “We expect returns from the funds infused within 6 to 8 months.”
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.